Research programme: checkpoint kinase 1 inhibitors - NovartisAlternative Names: CHIR 124
Latest Information Update: 19 Jul 2010
At a glance
- Originator Novartis
- Class Quinolones; Small molecules
- Mechanism of Action Phosphotransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
- 14 Apr 2004 Preclinical trials in Cancer in USA (unspecified route)